149 related articles for article (PubMed ID: 37000961)
21. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
22. Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
Aydemirli MD; van Eendenburg JDH; van Wezel T; Oosting J; Corver WE; Kapiteijn E; Morreau H
Endocr Relat Cancer; 2021 May; 28(6):377-389. PubMed ID: 33878728
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT
JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349
[TBL] [Abstract][Full Text] [Related]
24. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Wiedemann C; Kazdal D; Cvetkovic J; Kunz J; Fisch D; Kirchner M; Kriegsmann M; Sültmann H; Heussel CP; Bischoff H; Thomas M; Stenzinger A; Christopoulos P
Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36207130
[TBL] [Abstract][Full Text] [Related]
25. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
26. Lorlatinib in a Child with
Bagchi A; Orr BA; Campagne O; Dhanda S; Nair S; Tran Q; Christensen AM; Gajjar A; Furtado LV; Vasilyeva A; Boop F; Stewart C; Robinson GW
N Engl J Med; 2021 Aug; 385(8):761-763. PubMed ID: 34407349
[No Abstract] [Full Text] [Related]
27. Lorlatinib for the treatment of
Choo JR; Soo RA
Expert Rev Anticancer Ther; 2020 Apr; 20(4):233-240. PubMed ID: 32186215
[No Abstract] [Full Text] [Related]
28. A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.
Yan J; Zhou X; Pan D
Lung Cancer; 2020 Sep; 147():26-29. PubMed ID: 32652371
[TBL] [Abstract][Full Text] [Related]
29. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
[TBL] [Abstract][Full Text] [Related]
30. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
Sakakibara-Konishi J; Kitai H; Ikezawa Y; Hatanaka Y; Sasaki T; Yoshida R; Chiba S; Matsumoto S; Goto K; Mizugaki H; Shinagawa N
Clin Lung Cancer; 2019 Sep; 20(5):e555-e559. PubMed ID: 31307938
[No Abstract] [Full Text] [Related]
31. A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
Sharma GG; Cortinovis D; Agustoni F; Arosio G; Villa M; Cordani N; Bidoli P; Bisson WH; Pagni F; Piazza R; Gambacorti-Passerini C; Mologni L
J Thorac Oncol; 2019 Nov; 14(11):e257-e259. PubMed ID: 31668326
[No Abstract] [Full Text] [Related]
32. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
34. Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Smith S; Albuquerque de Almeida F; Inês M; Iadeluca L; Cooper M
Value Health; 2023 Jan; 26(1):64-70. PubMed ID: 35985941
[TBL] [Abstract][Full Text] [Related]
35. Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.
Kobayashi T; Kanda S; Fukushima T; Noguchi T; Sekiguchi N; Koizumi T
Thorac Cancer; 2021 Aug; 12(16):2275-2278. PubMed ID: 34184417
[TBL] [Abstract][Full Text] [Related]
36. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
37. Lorlatinib for the Treatment of ALK Fusion-Positive Infant-Type Hemispheric Glioma: A Case Report.
Greenwell AM; Baughan S; Altinok D; Marupudi NI; Kupsky W; Kumar-Sinha C; Gorsi HS
JCO Precis Oncol; 2022 Oct; 6():e2200255. PubMed ID: 36315913
[No Abstract] [Full Text] [Related]
38. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
39. ISOLATED VITREOUS METASTASIS IN A PATIENT WITH AN ANAPLASTIC LYMPHOMA KINASE-POSITIVE LUNG CANCER TREATED WITH LORLATINIB.
Suzani M; Benatti E; Ceola S; Coppola M
Retin Cases Brief Rep; 2024 Mar; 18(2):194-198. PubMed ID: 36228188
[TBL] [Abstract][Full Text] [Related]
40. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
